Back to catalogue
№ 077 25 filings · 2021-06-30 → 2026-05-11

CELLBXHEALTH PLC

CLBX
Health Care Market cap £35m Overall fit 165 /1000

Minimal AI-receiver exposure, fair (not cheap) valuation, theoretical-only operating leverage from a sub-scale loss-making base, and weak downside protection (going-concern risk, history of dilution) — does not fit the strategy's three pillars.

Fair value range 1p–2p Mid case · £11m
Absolute upside -70% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • November 2025 institutional placing at 1.0p sets fresh market clearing reference
  • Cash of £4.3m at March 2026 and £2.1m FY26 revenue guidance bound near-term valuation
  • FDA clearance and patented Parsortix IP provide a floor of option value
Limits the call
  • Multi-year track record of materially missing revenue guidance under prior management
  • Turnaround is in early innings under unproven new leadership with material further-dilution risk before stated 2028 EBITDA breakeven
Methodology

Forward EV/sales blended with cash runway and dilution-adjusted per-share floor

In one line · bull case

Recapitalised, FDA-cleared CTC diagnostics platform with a real (if narrow) £12.6m qualified pipeline and a leaner cost base that could inflect profit if conversion materialises before cash runs out.

In one line · biggest risk

Cash of £4.3m and burn against unproven turnaround execution under new management make further dilution before 2028 EBITDA breakeven the most probable adverse outcome.

Drivers
AI beneficiary 15 /100
No meaningful AI-receiver exposure; only an incidental Recursion Pharmaceuticals pilot and references to AI in cell-image analysis — value capture is not on this name.
Operating leverage 55 /100
High fixed-cost base (labs, R&D, central admin) post-restructuring would deliver disproportionate profit if revenue converts, but the company is still deeply loss-making so leverage is forward-looking.
Earnings vs expectations 8 /100
Repeated and material misses vs guidance (FY24 ~55% below consensus, FY25 cut from £3.0–3.7m to £1.6m), capped by management replacement.
Growth momentum 25 /100
Revenue fell ~45% from £2.9m (2024) to £1.6m (2025); FY26 guidance of £2.1m would still leave revenue below the FY24 print.
Moat 28 /100
Patented Parsortix tech and FDA clearance give differentiated IP but limited commercial moat — adoption has been slow and competition from ctDNA alternatives is real.
Earnings quality 22 /100
Persistent losses, reliance on R&D tax credits for cash, going-concern uncertainty noted in interims, non-cash FX volatility in opex.
Management quality 25 /100
Founder CEO and CFO resigned September 2025 following strategic failure; new leadership team is competent on paper but unproven in this role.
Cyclicality 30 /100
Diagnostics/healthcare end-market is defensive but customer base in biotech and academic research is highly funding-sensitive.
Leverage 18 /100
Net cash position post-November 2025 raise (£4.3m at March 2026) but cash burn means runway only to Q3 2027 on current plan.
Value-trap signals · 6
  • Three dilutive equity raises in 24 months at progressively lower prices (15p → 1.0p)
  • FY25 revenue declined materially vs FY24 with repeated guidance downgrades
  • Founder-CEO and CFO resigned September 2025 after strategic failure
  • Two corporate name changes/strategy resets in three years
  • Going-concern material uncertainty noted in H1 2025 interim financials
  • Accumulated losses of £142m versus modest commercial revenue

CelLBxHealth plc (CLBX) — Investment Research Note

Executive summary

CelLBxHealth (formerly ANGLE plc until October 2025) is a UK AIM-listed cancer diagnostics company that owns the patent-protected Parsortix® platform, which harvests intact circulating tumour cells (CTCs) from blood for use in pharma drug-development services, lab-developed tests, and product sales to CROs/clinical labs. The trajectory across the period is one of repeated strategic resets: revenue rose from £1.0m (2022) to £2.9m (2024), then collapsed back to £1.6m in 2025, prompting the resignation of the founder-CEO and CFO in September 2025, a 60% headcount reduction, a deeply dilutive £6.8m placing at 1.0p (a 38% discount and ~68% of enlarged share capital) and a rebrand. The single most important point for valuation today is that the equity has been recapitalised at distressed terms with cash of £4.3m at 31 March 2026 and management guiding £2.1m FY26 revenue against a stated path to EBITDA breakeven only by end-2028 — making this a binary turnaround bet with material going-concern risk.

Fair value estimate

  • Fair value range: 0.6p – 1.5p per share (implied market cap £6m – £15m).
  • Methodology: Forward EV/sales blend supplemented by a cash-runway sanity check. With ~1.03bn shares now in issue post placing, FY26 guidance of £2.1m and a peer multiple of 2.5–5x forward revenue (typical for sub-scale, unprofitable diagnostics with patented IP but unproven commercial model), enterprise value falls in a £5–10m range. Adding net cash of ~£4m gives a market-cap range of £6–15m. The mid-case fair value is broadly in line with the current £10.3m mcap.
  • Versus the £10.3m disclosed market cap: the shares sit roughly fair to slightly cheap on the mid-case, with absolute upside of approximately +5% to +45% at the high end and downside of roughly -40% at the low end.
  • Implied per-share fair value: approximately 1.0p mid (range 0.6p – 1.5p).

Sector context

ICB Health Care classification is confirmed. CLBX is materially worse than typical AIM diagnostics peers on every metric of quality: loss-making for many years, revenue trajectory broken, balance-sheet recapitalised at distressed terms, repeated dilution. Listed comparators include Oxford BioDynamics (OBD), Renalytix (RENX), and Inspiration Healthcare (IHC) — CLBX is broadly in the OBD/RENX cohort of liquid-biopsy/diagnostics micro-caps that have struggled to commercialise patented technology at scale.

Investment thesis (3 bullets)

  • Recapitalised platform with real IP and FDA clearance: Parsortix retains its first-ever FDA De Novo clearance (May 2022) for harvesting CTCs in metastatic breast cancer, with 115+ peer-reviewed publications and live collaborations with QIAGEN, Roche Diagnostics, Myriad Genetics and Illumina 2025-11-24 placing announcement. The £6.8m raise at 1.0p provides runway to Q3 2027 to convert these.
  • Pipeline visibility post restructuring: management discloses a £12.6m 2026/27 qualified sales pipeline (£4.5m risk-weighted), with FY26 guided to at least £2.1m revenue (+50%) supported by contracted revenues and near-term conversions, including a master services agreement under negotiation with a top-10 global pharma company and two US clinical studies with a major US healthcare provider 2026-05-11 Q1 trading update.
  • Operating-cost rebase creates leverage: headcount cut from over 100 (pre-restructuring) to 39 FTEs in Q1 2026, with annual cash operating costs reduced by over £6.6m in 2026 vs prior year 2026-05-11 Q1 trading update — meaning incremental revenue should drop disproportionately to operating profit if pipeline converts.

Key risks (3 bullets)

  • Going-concern / further dilution risk: even after the November 2025 raise, cash of £4.3m at 31 March 2026 against current burn implies runway only to Q3 2027 assuming revenue growth materialises; the company itself notes existing shareholders would face further dilution if a fresh raise is needed 2025-11-24 placing announcement risk factors. Existing shareholders have just been diluted by ~68% at a 38% discount.
  • Execution risk on revenue conversion: prior management materially missed guidance — FY24 was £2.9m vs original consensus £6.45m 2024-06-05 placing announcement, and FY25 collapsed to £1.6m. The new CEO (Peter Collins, appointed October 2025) has no prior track record at the helm of this business and the turnaround model has yet to demonstrate sustainable conversion.
  • Limited commercial moat despite IP: the technology has been commercially available since 2022 but a US$3.9bn US TAM thesis has not translated into materially recurring revenue; clinical adoption remains capital-constrained because large-scale utility trials are unfunded 2025-09-09 interim results.

Operating leverage

The cost base is highly fixed — central R&D, two GCLP/CLIA-aligned laboratories (UK and US, the latter now part-subleased), regulatory/quality infrastructure, and a small commercial team. Gross margins disclosed historically are 59-70%; H1 2025 gross margin was 59% on a service-heavy mix 2025-09-09 interim results. After the 2025/26 restructuring, annualised cash operating costs are roughly £10–11m (down from £16.9m FY24); against FY26 revenue guidance of £2.1m at ~60% gross margin, contribution is £1.3m versus the cost base — i.e. still loss-making. The operating-leverage point is forward-looking: if revenue grew 50-100% above the £2.1m base to £3–4m at preserved gross margin, incremental contribution (£0.5–1.1m) would compress losses meaningfully rather than create profit. To approach the company's stated EBITDA breakeven by end-2028, revenue plausibly needs to double again to ~£5–7m. The leverage exists in theory; the inflection point is the conversion of the £12.6m qualified pipeline. Cite 2025-11-24 placing announcement; 2026-05-11 trading update.

Value-trap signals

  • Sequential and severe revenue downgrades (FY24 consensus £6.45m → actual £2.9m → FY25 £1.6m guidance).
  • Three significantly dilutive equity raises in 24 months at progressively lower prices (June 2024 at 15p, November 2025 at 1.0p).
  • Founder-CEO and CFO resigned September 2025 following strategic failure; new team unproven.
  • Multiple corporate name changes and strategy resets (ANGLE → CelLBxHealth, October 2025).
  • Material uncertainty/going-concern language flagged in H1 2025 interim financial statements 2025-09-09 interim results.
  • Cumulative accumulated losses of £142m on roughly cumulative £150m+ of equity raised — chronic value destruction.
  • Sub-lease of part of US facility — capacity rationalisation, not growth.

Earnings vs. expectations

The pattern is one of consistent material misses. The 2023 results delivered revenue of £2.2m versus prior guidance of higher; January 2025 trading update stated FY24 revenue would be £2.9m (vs analyst consensus £6.45m noted in the June 2024 placing — a 55% miss); September 2025 interims downgraded FY25 from £3.0–3.7m (set in H1 2024) to "in excess of £1.5m", subsequently reset to £1.6m in November 2025; FDA clearance in May 2022 was hailed as transformational but generated less revenue than promised. In summary: management has missed top-line guidance in every reportable period across the filings, culminating in management change and a strategic reset.

Conviction

Conviction: 2 (low). My fair-value range is wide and rests on assumptions (pipeline conversion, gross-margin preservation, no further dilution before Q3 2027) where evidence quality is weak. Anchors: (i) the November 2025 placing price of 1.0p set by institutions provides a fresh market clearing reference; (ii) cash of £4.3m and stated £2.1m FY26 guidance give a narrow near-term financial anchor; (iii) clear IP and FDA clearance bound downside option value. Limiters: (i) the company has a multi-year track record of materially missing revenue guidance; (ii) new management is unproven and the turnaround is in inning one of nine; (iii) further dilution risk before EBITDA breakeven (end-2028 per management) is high given £4.3m cash against still-elevated burn.

Filings consulted · 23

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-11Q1 Trading Update And Outlook For 20262026-05-11_9560482_q1-trading-update-and-outlook-for-2026.md0.85
  2. 2026-04-30Confirmation OF Q1 Trading Update2026-04-30_9545361_confirmation-of-q1-trading-update.md0.85
  3. 2025-11-25Update TO Admission OF Fundraising Shares2025-11-25_9256767_update-to-admission-of-fundraising-shares.md0.70
  4. 2025-11-25Result OF Oversubscribed Placing And Subscription2025-11-25_9255411_result-of-oversubscribed-placing-and-subscription.md0.70
  5. 2025-11-24Proposed Placing And Subscription2025-11-24_9254164_proposed-placing-and-subscription.md0.70
  6. 2025-10-29Change OF Name2025-10-29_9200487_change-of-name.md0.51
  7. 2025-09-29Presentation OF Data ON Glioblastoma2025-09-29_9136039_presentation-of-data-on-glioblastoma.md0.59
  8. 2025-09-09Interim Results2025-09-09_9095148_interim-results.md0.77
  9. 2025-06-09Posting OF Annual Report And Notice OF Agm2025-06-09_8918419_posting-of-annual-report-and-notice-of-agm.md0.81
  10. 2025-01-23Trading Update2025-01-23_8701790_trading-update.md0.55
  11. 2024-09-26Half Year Report2024-09-26_8440227_half-year-report.md0.58
  12. 2024-09-17Notice OF Interim Results And Webcast2024-09-17_8419892_notice-of-interim-results-and-webcast.md0.58
  13. 2024-06-18Posting OF 2023 Annual Report Amp Notice OF The Agm2024-06-18_8266032_posting-of-2023-annual-report-amp-notice-of-the-agm.md0.62
  14. 2024-06-05Results OF Placing And Subscription2024-06-05_8244622_results-of-placing-and-subscription.md0.46
  15. 2024-06-05Proposed Placing Subscription And Open Offer2024-06-05_8242638_proposed-placing-subscription-and-open-offer.md0.46
  16. 2023-09-07Interim Results For The Period Ended 30 June 20232023-09-07_7740255_interim-results-for-the-period-ended-30-june-2023.md0.41
  17. 2023-08-15Angle Notice OF Interim Results2023-08-15_7695851_angle-notice-of-interim-results.md0.41
  18. 2022-09-29Interim Results2022-09-29_7169007_interim-results.md0.23
  19. 2022-09-01Notice OF Interim Results And Webcast2022-09-01_7163480_notice-of-interim-results-and-webcast.md0.23
  20. 2022-07-14Proposed Placing And Retail Offer2022-07-14_7032512_proposed-placing-and-retail-offer.md0.17
  21. 2021-09-30Interim Results2021-09-30_6598938_interim-results.md0.23
  22. 2021-09-07Notice OF Interim Results And Webcast2021-09-07_6721603_notice-of-interim-results-and-webcast.md0.23
  23. 2021-06-30Result OF Agm2021-06-30_6472154_result-of-agm.md0.07

This research note was authored by a large language model after reading 25 regulatory filings published between 2021-06-30 and 2026-05-11. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.